EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Beyond Air, Inc (XAIR) fair value: what the stock is really worth

As of Oct 7, 2026: fair value of Beyond Air, Inc $3.48, price $2.54, upside +37.0%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US08862L3015

BA Beyond Air, Inc logo Thin data Oct 3, 2026

Beyond Air, Inc

XAIR · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

Fair value $3.48 · Undervalued (+37.0%)
Quality 40/100
Mixed Growth (revenue 5y +54.5 %/yr in USD)
Mixed vs. peers (4/8)
High debt
Negative free cash flow
Thin data
Watch Beyond Air, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$6,244 $2.54 Fair Value $3.48 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range $2.54 – $6,244 · fair‑value band $2.59 – $5.19 · the $2.54 price screens below the $3.48 fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Beyond Air in your weekly email

Every Wednesday you see whether Beyond Air is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn.

Show more

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Stock analysis

Beyond Air, Inc (XAIR) currently trades at $2.54, while our model-based Fair Value estimate is $3.48, implying the stock looks roughly 27.0% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $2.59 (bear) to $5.19 (bull), the price of $2.54 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Beyond Air, Inc reported revenue of $7.7M in FY2026 versus $145K in FY2022, a compound +169.7%/yr. Reported net income was −$33.2M in FY2026.

Key figures

Market cap $2.8M · P/E ratio 0.0 · P/S ratio 0.36 · EPS (TTM) $−60.53 · Return on equity −520% · Return on assets (EBIT) −91.5% · Operating margin −374% · Revenue (TTM) $7.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 95% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 37%, XAIR screens cheaper than that median.

Fair Value models

Bear $2.59 Fair Value $3.48 Bull $5.19
Price $2.54 · Upside +37.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $3.11 $4.17 $6.22 54
All 1 models by family
Asset-Based
NCAV (Graham) $3.11 $4.17 $6.22 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

Of which business quality 40 · Market factors (momentum, volatility) 15

Profitability 1
Margins and returns on capital today
Quality Growth 99
Are margins and returns improving?
Cashflow 1
Earnings quality: real cash, not paper profit
Fin. Strength 19
Balance sheet, leverage, solvency risk
Investment 79
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+107.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+406.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+54.5%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,544.6% (2021) → −378.2% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch XAIR, get fair value alerts →

Compare Beyond Air, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 328 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside +37.0% · Top 25%
Profitability
Return on assets −57.5% · Bottom 25%
Growth and dividend
Revenue growth 0.5% · Below median
Balance sheet
Debt / equity 3.53× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 0.0× · Cheapest 25%
P/B 0.45× · Cheapest 25%
P/S (TTM) 0.36× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)83 · sector 8
FUTURE (revenue growth)3 · sector 31
PAST (return on equity)0 · sector 17
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $275.43 $302.97 +10% vs XAIR
Boston Scientific Corporation BSX $42.19 $46.41 +10% vs XAIR
DexCom, Inc DXCM $85.36 $93.90 +10% vs XAIR
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10% vs XAIR
STERIS plc STE $208.93 $229.82 +10% vs XAIR
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6% vs XAIR
Edwards Lifesciences Corporation EW $85.19 $81.94 −4% vs XAIR
Medtronic plc MDT $86.38 $65.61 −24% vs XAIR
Abbott Laboratories, ABT $100.10 $74.79 −25% vs XAIR
Koninklijke Philips N.V PHIA €21.87 €15.23 −30% vs XAIR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beyond Air, Inc · Fair Value
$3.48 +27%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Beyond Air, Inc Fair Value". https://www.fairvalue-calculator.com/stock/XAIR

Frequently asked questions

Is Beyond Air, Inc (XAIR) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $3.48 versus a price of $2.54, about +37% upside (undervalued).
What is the fair value of XAIR?
Our model-based fair value for Beyond Air, Inc is $3.48 (as of Oct 3, 2026), built from audited fundamentals. The current price: $2.54.
What is the quality score of XAIR?
Beyond Air, Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beyond Air, Inc (XAIR)?
Our model-based price target is the fair value of $3.48 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario $2.59, optimistic scenario $5.19. It is a calculation from audited fundamentals, not an analyst target.
What is the Beyond Air, Inc stock forecast for 2026?
Our models put fair value at $3.48, about +37% upside versus a price of $2.54 (undervalued). Cautious scenario $2.59, optimistic scenario $5.19. The calculation is refreshed regularly with new filings.
What is the revenue of Beyond Air, Inc (XAIR)?
Beyond Air, Inc reported trailing-twelve-month revenue of about $7.7M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Beyond Air, Inc (XAIR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beyond Air, Inc it is $3.48 per share (as of Oct 3, 2026), against a price of $2.54. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Beyond Air, Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, XAIR trades below its calculated fair value: price $2.54, fair value $3.48, a gap of about +37% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XAIR?
No. The price is what the market pays today ($2.54); the fair value is what the company's own numbers justify ($3.48). For Beyond Air, Inc the two are $0.9400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beyond Air, Inc worth?
The market values Beyond Air, Inc at about $2.8M (market capitalisation, as of Oct 3, 2026). Per share that is $2.54; our models calculate a fair value of $3.48 per share.
What do the bullish and bearish scenarios say about XAIR?
Our models span a range for Beyond Air, Inc: cautious scenario $2.59, base $3.48, optimistic $5.19 per share (as of Oct 3, 2026, price $2.54). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of XAIR?
Beyond Air, Inc trades at a price-to-earnings ratio of 0.0 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.48 is built from several models across several years. Other multiples: P/B 0.5, P/S 0.4.
How solid is the balance sheet of Beyond Air, Inc (XAIR)?
Balance-sheet figures for Beyond Air, Inc (as of Oct 3, 2026): debt of 3.53 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is XAIR from its 52-week high?
Beyond Air, Inc trades at $2.54, about 95% below its 52-week high of $54.00 and at the low of $2.54 (as of Oct 7, 2026). Distance from the high says nothing about value: that is what the fair value of $3.48 is for.
Which stocks are comparable to Beyond Air, Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beyond Air, Inc stock attractive at the current price?
The data as of Oct 3, 2026: price $2.54, calculated fair value $3.48 (+37%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XAIR calculated?
We run Beyond Air, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.48, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.3 % above its aggregate fair value. Beyond Air, Inc currently trades 27 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beyond Air, Inc (XAIR)?
The closing price on Oct 7, 2026 was $2.54. Our model-based fair value is $3.48, about +37% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beyond Air, Inc right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.59 to $5.19) leaves room in how you read the outcome.

Key figures of Beyond Air, Inc

How large is the market capitalisation of Beyond Air, Inc (XAIR)?
The market capitalisation of Beyond Air, Inc is $2.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beyond Air, Inc (XAIR)?
The price-to-sales ratio of Beyond Air, Inc is 0.36 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beyond Air, Inc (XAIR)?
Earnings per share at Beyond Air, Inc are $−60.53 (price ÷ EPS = P/E 0.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Beyond Air, Inc (XAIR)?
The return on equity (ROE) of Beyond Air, Inc is −520% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beyond Air, Inc (XAIR)?
On an EBIT basis the return on assets of Beyond Air, Inc is −91.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beyond Air, Inc (XAIR)?
The operating margin of Beyond Air, Inc is −374% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beyond Air, Inc (XAIR)?
Revenue at Beyond Air, Inc is growing +0.5% versus a year earlier (3y avg +407%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Beyond Air, Inc (XAIR) generate?
The free cash flow of Beyond Air, Inc is −$19.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Beyond Air, Inc (XAIR) carry?
The net debt of Beyond Air, Inc is $16.6M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Beyond Air, Inc in the live analysis

One click puts Beyond Air, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.